China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease
China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis or Crohn’s disease who have had an inadequate or lost response to, or were intolerant of, conventional therapies.
The President of Takeda, Sean Shan, commented on the approval and said: “Many thanks to the NMPA for officially approving the availability of Entyvio for China’s patients. Its approval brings more treatment options to clinicians, and will enable more IBD patients to return to their normal daily lives.
“The Chinese government’s determination to significantly improve access of innovative drugs, and to improve peoples’ quality of life is crystal clear. Including Entyvio in the first list of ‘urgently needed’ overseas drugs, and its accelerated approval process is a clear example of this. For our part, Takeda is committed to continuing to develop and make available highly innovative medicines and will bring these novel solutions to China’s patients as fast as possible.”
Entyvio is a gut-selective biologic which inhibits the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1. By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues, and these cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis and Crohn’s disease.
Crohn’s disease and ulcerative colitis are two of the most common forms of inflammatory bowel disease. Crohn’s can affect any part GI tract and can affect the thickness of the bowel wall. Comparatively, ulcerative colitis only affects the large intestine and only involves its innermost lining.
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which …